Replies to post #1663 on Vascular Biogenics Ltd (VBLT)

[SCHB]

Let's presume, staccani, that they are being dishonest with those numbers you cited. If the smaller numbers were replicated in a phase 3 trial for rGBM, would they be good enough for approval? By that I mean, the are the non-inflated numbers still good enough?

[Oren1976]

About the gbm they moved to speak 59 weeks but u may be right and here and there we still hear 15 months but ovarian I don't remember him mentioning 810 days in the past year and a half. When was the last time they talked 810 as median ? Also I think u urself doubted ur own conclusion in some way back then in case people continue to stay alive and I remember and can't find a reply to ur claim by members here explaining u did wrong determining the mos in ur calculations. Can u remind me pls what was ur own claim and what was the other member claim criticizing ur 810 false median statement ?

[mantoo123]

I don't think most investors look at the actual number of months of OS to decide whether to invest or not. Moreover, no one is going to jail for having published OS values in units of weeks instead of months or vice versa.

Regarding VB-111, there is an ongoing phase 3 trial for rGBM under an SPA with the FDA. The p3 tiral is what makes investors take the plunge.

Regarding CEO credibility:

Prof. Harats has an illustrious career as a medical doctor, a researcher at Tel Hashomer, Israel's largest hospital, and as a faculty member at Tel-Aviv university.

He is also surrounded by high calibre people with years of experience in clinical trials and related fields.

I understand that the ability to prosecute and jail a CEO might be reassuring to some investors. However, we can assume that there exist guarantees put in place by the SEC so that US investors are not easily scammed. Admittedly, I do not know the actual guarantees involved.

Notwithstanding the above, it is entirely possible that VB-111 is a dud as many have claimed in the past. We will find out shortly.